IP Verse

Mitsubishi Tanabe Pharma Corporation opposition analysis

COMPANY ANALYSIS

Patent:

Grant Date:

Oct 7, 2020

Title:

Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Glucose Transporter

Oppositions:

Patent:

Grant Date:

Oct 23, 2019

Title:

Combination Therapy Comprising Sglt Inhibitors And Dpp4 Inhibitors

Oppositions:

Patent:

Grant Date:

Apr 3, 2019

Title:

Medicinal Agent For Treating Amyotrophic Lateral Sclerosis Or Preventing Progression Of Phase Of Amyotrophic Lateral Sclerosis

Oppositions:

Patent:

Grant Date:

Mar 28, 2018

Title:

Novel Therapeutic Agent For Amyotrophic Lateral Sclerosis (Als) Or Disease Attributable To Als

Oppositions:

Patent Number	Grant Date	Title	Total Oppositions
EP2896397	Oct 7, 2020	Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Glucose Transporter	2
EP2252289	Oct 23, 2019	Combination Therapy Comprising Sglt Inhibitors And Dpp4 Inhibitors	1
EP2754440	Apr 3, 2019	Medicinal Agent For Treating Amyotrophic Lateral Sclerosis Or Preventing Progression Of Phase Of Amyotrophic Lateral Sclerosis	1
EP1714960	Mar 28, 2018	Novel Therapeutic Agent For Amyotrophic Lateral Sclerosis (Als) Or Disease Attributable To Als	1

MAIWALD GMBH

ELKINGTON AND FIFE LLP

GALENICUM HEALTH S.L.

Feel free to send us a message here and we will get back to you